Abstract
For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Current Topics in Medicinal Chemistry
Title: Structure-Activity Relationships of Selective GABA Uptake Inhibitors
Volume: 6 Issue: 17
Author(s): Signe Hog, Jeremy R. Greenwood, Karsten B. Madsen, Orla M. Larsson, Bente Frolund, Arne Schousboe, Povl Krogsgaard-Larsen and Rasmus P. Clausen
Affiliation:
Keywords: Acyclic GABA Analogues, THPO, Nipecotic Acid, Aminocyclohexanecarboxylic Acid (ACHC), GABA uptake assay
Abstract: For more than four decades there has been a search for selective inhibitors of GABA transporters. This has led to potent and selective inhibitors of the cloned GABA transporter subtype GAT1, which is responsible for a majority of neuronal GABA transport. The only clinically approved compound with this mechanism of action is Tiagabine. Other GABA transporter subtypes have not been targeted with comparable selectivity and potency. We here review a comprehensive series of competitive inhibitors that provide information about the GABA recognition site and summarise the structure-activity relations in a ligand-based pharmacophore model that suggests how future compounds could be designed. Finally, some of the recent results on subtype-characterised competitive inhibitors and recent lipophilic aromatic GABA uptake inhibitors are reviewed.
Export Options
About this article
Cite this article as:
Hog Signe, Greenwood R. Jeremy, Madsen B. Karsten, Larsson M. Orla, Frolund Bente, Schousboe Arne, Krogsgaard-Larsen Povl and Clausen P. Rasmus, Structure-Activity Relationships of Selective GABA Uptake Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (17) . https://dx.doi.org/10.2174/156802606778249801
DOI https://dx.doi.org/10.2174/156802606778249801 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research In-vitro Functionality of Clozapine Biphasic Release Minitablet Using Advanced Statistical Tools
Drug Delivery Letters Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Role of Vitamins in Neurodegenerative Diseases: A Review
CNS & Neurological Disorders - Drug Targets Bis-dihydroisoxazolines: Synthesis, Structural Elucidation, Antimicrobial Evaluation, and DNA Photocleavage Assay
Current Organic Synthesis GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors
Current Gene Therapy High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology New Perspectives on the Structure and Function of the Na+ Channel Multigene Family
Current Medicinal Chemistry - Central Nervous System Agents Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Lamotrigine Induced Whole Body Tics: A Case Report and Literature Review
Current Drug Safety Are Raw Scores on Memory Tests Better than Age- and Education- Adjusted Scores for Predicting Progression from Amnesic Mild Cognitive Impairment to Alzheimer Disease ?
Current Alzheimer Research Intracranial Cerebrospinal Fluid Volume Evaluation in Healthy People and Hydrocephalus Patients using SPACE Sequence
Current Medical Imaging Microendophenotypes of Psychiatric Disorders: Phenotypes of Psychiatric Disorders at the Level of Molecular Dynamics, Synapses, Neurons, and Neural Circuits
Current Molecular Medicine Antioxidants as a Preventive Treatment for Epileptic Process: A Review of the Current Status
Current Neuropharmacology Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity
Current Pharmaceutical Design Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets Latest Advances Towards the Discovery of 5-HT7 Receptor Ligands
Mini-Reviews in Medicinal Chemistry